Kathleen A M Rose1, Jaime H Vera, Peter Drivas, Winston Banya, Niall Keenan, Dudley J Pennell, Alan Winston. 1. *Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, United Kingdom; †Section of Infectious Diseases, Department of Medicine, Imperial College London, London, United Kingdom; and ‡Division of Medicine, Brighton and Sussex Medical School, United Kingdom.
Abstract
OBJECTIVE: Premature atherosclerosis has been observed among HIV-infected individuals with high cardiovascular risk using one-dimensional ultrasound carotid intima-media thickness. We evaluated the assessment of HIV-infected individuals with low traditional cardiovascular disease risk using cardiovascular magnetic resonance, which allows three-dimensional assessment of the carotid artery wall. METHODS: Carotid cardiovascular magnetic resonance was performed in 33 HIV-infected individuals (cases) (19 male, 14 female), and 35 HIV-negative controls (20 male, 15 female). Exclusion criteria included smoking, hypertension, hyperlipidemia (total cholesterol/HDL ratio > 5) or family history of premature atherosclerosis. Cases were stable on combination antiretroviral therapy with plasma HIV-1 RNA <50 copies per milliliter. Using computer modeling, the arterial wall, lumen, and total vessel volumes were calculated for a 4-cm length of each carotid artery centered on the bifurcation. The wall/outer-wall ratio (W/OW), an index of vascular thickening, was compared between the groups. RESULTS: Cases had a median CD4 cell count of 690 cells per microliter. Mean (±SD) age and 10-year Framingham coronary risk scores were similar for cases and controls (45.2 ± 9.7 years versus 46.9 ± 11.6 years and 3.97% ± 3.9% versus 3.72% ± 3.5%, respectively). W/OW was significantly increased in cases compared with controls (36.7% versus 32.5%, P < 0.0001); this was more marked in HIV-infected females. HIV status was significantly associated with increased W/OW after adjusting for age (P < 0.0001). No significant association between antiretroviral type and W/OW was found-W/OW lowered comparing abacavir to zidovudine (P = 0.038), but statistical model fits poorly. CONCLUSIONS: In a cohort of treated HIV-infected individuals with low measurable cardiovascular risk, we have observed evidence of premature subclinical atherosclerosis.
OBJECTIVE:Premature atherosclerosis has been observed among HIV-infected individuals with high cardiovascular risk using one-dimensional ultrasound carotid intima-media thickness. We evaluated the assessment of HIV-infected individuals with low traditional cardiovascular disease risk using cardiovascular magnetic resonance, which allows three-dimensional assessment of the carotid artery wall. METHODS: Carotid cardiovascular magnetic resonance was performed in 33 HIV-infected individuals (cases) (19 male, 14 female), and 35 HIV-negative controls (20 male, 15 female). Exclusion criteria included smoking, hypertension, hyperlipidemia (total cholesterol/HDL ratio > 5) or family history of premature atherosclerosis. Cases were stable on combination antiretroviral therapy with plasma HIV-1 RNA <50 copies per milliliter. Using computer modeling, the arterial wall, lumen, and total vessel volumes were calculated for a 4-cm length of each carotid artery centered on the bifurcation. The wall/outer-wall ratio (W/OW), an index of vascular thickening, was compared between the groups. RESULTS: Cases had a median CD4 cell count of 690 cells per microliter. Mean (±SD) age and 10-year Framingham coronary risk scores were similar for cases and controls (45.2 ± 9.7 years versus 46.9 ± 11.6 years and 3.97% ± 3.9% versus 3.72% ± 3.5%, respectively). W/OW was significantly increased in cases compared with controls (36.7% versus 32.5%, P < 0.0001); this was more marked in HIV-infected females. HIV status was significantly associated with increased W/OW after adjusting for age (P < 0.0001). No significant association between antiretroviral type and W/OW was found-W/OW lowered comparing abacavir to zidovudine (P = 0.038), but statistical model fits poorly. CONCLUSIONS: In a cohort of treated HIV-infected individuals with low measurable cardiovascular risk, we have observed evidence of premature subclinical atherosclerosis.
Authors: Anitha Varghese; Lindsey A Crowe; Raad H Mohiaddin; Peter D Gatehouse; Guang Zhong Yang; David M Nott; James M McCall; David N Firmin; Dudley J Pennell Journal: J Magn Reson Imaging Date: 2005-02 Impact factor: 4.813
Authors: Vasily L Yarnykh; Masahiro Terashima; Cecil E Hayes; Ann Shimakawa; Norihide Takaya; Patricia K Nguyen; Jean H Brittain; Michael V McConnell; Chun Yuan Journal: J Magn Reson Imaging Date: 2006-05 Impact factor: 4.813
Authors: Roberto Corti; Valentin Fuster; Zahi A Fayad; Stephen G Worthley; Gerard Helft; William F Chaplin; Jörg Muntwyler; Juan F Viles-Gonzalez; Jesse Weinberger; Donald A Smith; Gabor Mizsei; Juan J Badimon Journal: J Am Coll Cardiol Date: 2005-07-05 Impact factor: 24.094
Authors: L E Chambless; G Heiss; A R Folsom; W Rosamond; M Szklo; A R Sharrett; L X Clegg Journal: Am J Epidemiol Date: 1997-09-15 Impact factor: 4.897
Authors: Priscilla Y Hsue; Joan C Lo; Arlana Franklin; Ann F Bolger; Jeffrey N Martin; Steven G Deeks; David D Waters Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Dima A Hammoud; Sanhita Sinharay; Sally Steinbach; Paul G Wakim; Katrina Geannopoulos; Katherine Traino; Amit K Dey; Edmund Tramont; Stanley I Rapoport; Joseph Snow; Nehal N Mehta; Bryan R Smith; Avindra Nath Journal: Neurology Date: 2018-09-26 Impact factor: 9.910
Authors: Chanelle M Diaz; Eddy R Segura; Paula M Luz; Jesse L Clark; Sayonara R Ribeiro; Raquel De Boni; Leonardo Eksterman; Rodrigo Moreira; Judith S Currier; Valdiléa G Veloso; Beatriz Grinsztejn; Jordan E Lake Journal: BMC Infect Dis Date: 2016-08-08 Impact factor: 3.090